EMBOLD Study
Phase 1/2 study to evaluate the safety and efficacy of ATA188 in subjects with progressive multiple sclerosis
REQUEST INFO
Clinical studies are essential for investigating new therapies, and patient participants are essential for moving trials forward. If you are interested in learning more about one of our ongoing studies, please speak with your doctor or contact us for more information.
*EBV-associated diseases being studied include: EBV+ lymphoproliferative disease (LPD) in the setting of primary immunodeficiency (PID) (PID LPD); EBV+ LPD in the setting of acquired (non-congenital) immunodeficiency (AID) (AID LPD); EBV+ posttransplant lymphoproliferative disorder involving the central nervous system (CNS PTLD); EBV+ PTLD where standard first line therapy (rituximab or chemotherapy) is not appropriate, including CD20 negative disease; EBV+ sarcomas, including leiomyosarcoma (LMS); chronic active EBV (CAEBV) and EBV+ hemophagocytic lymphohistiocytosis (HLH) (CAEBV/HLH cohort).
The safety and efficacy of the investigational use of these products have not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.
EBV=Epstein-Barr virus; EBV+=EBV positive; HLA=human leukocyte antigens; MS=multiple sclerosis; PTLD=post-transplant lymphoproliferative disease.